Citations

Mayo Clinic

Showing 10 of 108551 citations.

Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis
Molina‐Infante, Javier , Bredenoord, Albert J. , Cheng, Edaire , Dellon, Evan S. , Furuta, Glenn T. , Gupta, Sandeep K. , Hirano, Ikuo , Katzka, David A. , Moawad, Fouad J. , Schoepfer, Alain , Wen, Ting , Straumann, Alex , Rothenberg, Marc E. , Spechler, Stuart Jon , Lucendo, Alfredo

Gut | December 19, 2015 | Volume: 65 | Issue: 3 | Pages: 524-531

10.1136/gutjnl-2015-310991 | PMID 26685124 Get It

Consensus diagnostic recommendations to distinguish GORD from eosinophilic oesophagitis (EoE) by response to a trial of proton pump inhibitors (PPIs) unexpectedly uncovered an entity called ‘PPI-responsive oesophageal eosinophilia’ (PPI-REE). PPI-REE refers to patients with clinical and histological features of EoE that remit with PPI treatment. Recent and evolving evidence, mostly from adults, shows that patients with PPI-REE and patients with EoE at baseline are clinically, endoscopically and histologically indistinguishable and have a significant overlap in terms of features of Th2 immune-mediated inflammation and gene expression. Furthermore, PPI therapy restores oesophageal mucosal integrity, reduces Th2 inflammation and reverses the abnormal gene expression signature in patients with PPI-REE, similar to the effects of topical steroids in patients with EoE. Additionally, recent series have reported that patients with EoE responsive to diet/topical steroids may also achieve remission on PPI therapy. This mounting evidence supports the concept that PPI-REE represents a continuum of the same immunological mechanisms that underlie EoE. Accordingly, it seems counterintuitive to differentiate PPI-REE from EoE based on a differential response to PPI therapy when their phenotypic, molecular, mechanistic and therapeutic features cannot be reliably distinguished. For patients with symptoms and histological features of EoE, it is reasonable to consider PPI therapy not as a diagnostic test, but as a therapeutic agent. Due to its safety profile, ease of administration and high response rates (up to 50%), PPI can be considered a first-line treatment before diet and topical steroids. The reasons why some patients with EoE respond to PPI, while others do not, remain to be elucidated.
Treatment of Peroneal Nerve Injuries in the Multiligament Injured/Dislocated Knee
O’Malley, Michael, Pareek, Ayoosh , Reardon, Patrick J., Krych, Aaron J. , Levy, Bruce A. , O'Malley, Michael P, Reardon, Patrick, Stuart, Michael J. , Krych, Aaron J

Journal of Knee Surgery | December 18, 2015 | Volume: 29 | Issue: 04 | Pages: 287-292

10.1055/s-0035-1570019 | PMID 26683981 Get It

Mobile spine chordoma: results of 166 patients from the AOSpine Knowledge Forum Tumor database
Gokaslan, Ziya L., Zadnik, Patricia L., Sciubba, Daniel M. , Germscheid, Niccole, Goodwin, C. Rory , Wolinsky, Jean‐Paul , Groves, Mari L. , Luzzati, Alessandro , Rhines, Laurence D. , Fisher, Charles G. , Varga, Péter , Dekutoski, Mark B. , Fehlings, Michael G. , Quraishi, Nasir A. , Chou, Dean , Reynolds, Jeremy , Williams, Richard P., Kawahara, Norio , Boriani, Stefano , Reynolds, Jeremy , Bettegowda, Chetan , Clarke, Michelle J. , Fehlings, Michael G , Goodwin, C Rory , Reynolds, Jeremy

Journal of Neurosurgery: Spine | December 18, 2015 | Volume: 24 | Issue: 4 | Pages: 644-651

10.3171/2015.7.spine15201 | PMID 26682601 Get It

OBJECT A chordoma is an indolent primary spinal tumor that has devastating effects on the patient's life. These lesions are chemoresistant, resistant to conventional radiotherapy, and moderately sensitive to proton therapy; however, en bloc resection remains the preferred treatment for optimizing patient outcomes. While multiple small and largely retrospective studies have investigated the outcomes following en bloc resection of chordomas in the sacrum, there have been few large-scale studies on patients with chordomas of the mobile spine. The goal of this study was to review the outcomes of surgically treated patients with mobile spine chordomas at multiple international centers with respect to local recurrence and survival. This multiinstitutional retrospective study collected data between 1988 and 2012 about prognosis-predicting factors, including various clinical characteristics and surgical techniques for mobile spine chordoma. Tumors were classified according to the Enneking principles and analyzed in 2 treatment cohorts: Enneking-appropriate (EA) and Enneking-inappropriate (EI) cohorts. Patients were categorized as EA when the final pathological assessment of the margin matched the Enneking recommendation; otherwise, they were categorized as EI. METHODS Descriptive statistics were used to summarize the data (Student t-test, chi-square, and Fisher exact tests). Recurrence and survival data were analyzed using Kaplan-Meier survival curves, log-rank tests, and multivariate Cox proportional hazard modeling. RESULTS A total of 166 patients (55 female and 111 male patients) with mobile spine chordoma were included. The median patient follow-up was 2.6 years (range 1 day to 22.5 years). Fifty-eight (41%) patients were EA and 84 (59%) patients were EI. The type of biopsy (p < 0.001), spinal location (p = 0.018), and if the patient received adjuvant therapy (p < 0.001) were significantly different between the 2 cohorts. Overall, 58 (35%) patients developed local recurrence and 57 (34%) patients died. Median survival was 7.0 years postoperative: 8.4 years postoperative for EA patients and 6.4 years postoperative for EI patients (p = 0.023). The multivariate analysis showed that the EI cohort was significantly associated with an increased risk of local recurrence in comparison with the EA cohort (HR 7.02; 95% CI 2.96–16.6; p < 0.001), although no significant difference in survival was observed. CONCLUSIONS EA resection plays a major role in decreasing the risk for local recurrence in patients with chordoma of the mobile spine.
MicroRNA-21 Aggravates Cyst Growth in a Model of Polycystic Kidney Disease
Lakhia, Ronak , Hajarnis, Sachin, Aboudehen, Karam , Yheskel, Matanel , Xing, Chao , Hatley, Mark E. , Torres, Vicente E. , Wallace, Darren P. , Patel, Vishal , Williams, Darren R. , Torres, Vicente E , Wallace, Darren P , Patel, Vishal , Xing, Chao

Journal of the American Society of Nephrology | December 18, 2015 | Volume: 27 | Issue: 8 | Pages: 2319-2330

10.1681/asn.2015060634 | PMID 26677864 Get It

Autosomal dominant polycystic kidney disease (ADPKD), one of the most common monogenetic disorders, is characterized by kidney failure caused by bilateral renal cyst growth. MicroRNAs (miRs) have been implicated in numerous diseases, but the role of these noncoding RNAs in ADPKD pathogenesis is still poorly defined. Here, we investigated the role of miR-21, an oncogenic miR, in kidney cyst growth. We found that transcriptional activation of miR-21 is a common feature of murine PKD. Furthermore, compared with renal tubules from kidney samples of normal controls, cysts in kidney samples from patients with ADPKD had increased levels of miR-21. cAMP signaling, a key pathogenic pathway in PKD, transactivated miR-21 promoter in kidney cells and promoted miR-21 expression in cystic kidneys of mice. Genetic deletion of miR-21 attenuated cyst burden, reduced kidney injury, and improved survival of an orthologous model of ADPKD. RNA sequencing analysis and additional in vivo assays showed that miR-21 inhibits apoptosis of cyst epithelial cells, likely through direct repression of its target gene programmed cell death 4 . Thus, miR-21 functions downstream of the cAMP pathway and promotes disease progression in experimental PKD. Our results suggest that inhibiting miR-21 is a potential new therapeutic approach to slow cyst growth in PKD.
Cutting the brakes and flooring the gas: how TMEPAI turns TGF-β into a tumor promoter
Cichon, Magdalena A., Radisky, Derek C.

Genes & Cancer | December 17, 2015 | Volume: 5 | Issue: 9-10 | Pages: 303-305

10.18632/genesandcancer.34 | PMID 25352947 Get It

Serum Parathyroid Hormone Concentrations and Clinical Outcomes in ESRD: A Call for Targeted Clinical Trials
Zand, Ladan , Kumar, Rajiv , Kumar, Rajiv

Seminars in Dialysis | December 17, 2015 | Volume: 29 | Issue: 3 | Pages: 184-188

10.1111/sdi.12457 | PMID 26676210 Get It

AbstractSecondary hyperparathyroidism almost universally accompanies end‐stage renal disease (ESRD). In some, but not all studies, elevated serum parathyroid hormone (PTH) concentrations are associated with increased fracture rates, cardiovascular disease, and mortality in ESRD. The serum concentration of PTH required for optimal bone health and reduced cardiovascular risk in such patients remains elusive. Recent clinical trials have failed to show substantial changes in morbidity and mortality following reductions of elevated serum PTH concentrations. In this review, we will assess some of the difficulties in evaluating elevated serum PTH concentrations, and their association with skeletal fractures and mortality in ESRD patients. We are of the opinion that in the context of ESRD, elevated PTH concentrations occur in conjunction with other comorbid conditions such as diabetes mellitus, malnutrition, hypertension, volume excess, preexisting heart disease, all of which have prevented establishing a precise association between elevated serum PTH concentrations and global or skeletal outcomes. Age, gender, and racial variability among groups make interpretation exceptionally difficult. Analysis of prevalent ESRD populations with secondary hyperparathyroidism should take all these factors into account. We suggest that future clinical trials which examine the usefulness of reductions in serum PTH concentrations be conducted in age, sex, and racially balanced groups, without or with minimal coexisting confounding disease. Furthermore, trials in such populations should have as their primary outcome a reduction in fractures rather than an alteration in mortality.
Frequency of cutis laxa‐like clinical features and elastolysis in scleromyxedema: a retrospective clinicopathologic study of 19 patients with scleromyxedema
Santiago, Tania M. González, Lehman, Julia S. , Buonaccorsi, J. Noelle, Kalaaji, Amer N., Wieland, Carilyn N. , Gonzalez Santiago, Tania M, Lehman, Julia S

Journal of Cutaneous Pathology | December 17, 2015 | Volume: 43 | Issue: 3 | Pages: 246-251

10.1111/cup.12657 | PMID 26676919 Get It

BackgroundCutis laxa‐like features were observed in a subset of patients with scleromyxedema. Given this observation, clinical and histopathologic features of scleromyxedema were reviewed in correlation with elastic tissue staining.MethodsWe retrospectively reviewed clinical records and histopathologic features from patients with scleromyxedema seen at our institution from 1992 through 2013. We also evaluated available skin biopsies with an elastin stain and assessed whether dermal elastin fibers were diminished in density or were fragmented (or both).ResultsNineteen patients with scleromyxedema and 34 skin biopsies were identified. Alcian blue (mucin) stain was used to grade mucin deposition as weakly positive (24%), positive (44%) and markedly positive (32%). Eight patients (42%) had clinical findings of cutis laxa, which were often observed in conjunction with areas of papular eruption or induration. Elastic tissue fibers were normal in 9 of 34 skin specimens (26%), 18 of 34 specimens (53%) had diminished elastic fiber density and 7 of 34 (21%) had markedly decreased density. The elastic tissue was fragmented in 25 specimens (74%).ConclusionsA cutis laxa‐like clinical presentation and decreased elastic tissue density on skin biopsy were consistent findings. Dermatologists and dermatopathologists should be aware of these previously unreported clinical and histopathologic findings.
Rare variants in MC1R/TUBB3 exon 1 are not associated with Parkinson's disease
Lorenzo‐Betancor, Oswaldo , Ross, Owen A. , Wszołek, Zbigniew K. , Ross, Owen A

Annals of Neurology | December 17, 2015 | Volume: 79 | Issue: 2 | Pages: 331-331

10.1002/ana.24581 | PMID 26677074 Get It

Discriminating long myelitis of neuromyelitis optica from sarcoidosis
Flanagan, Eoin P. , Krecke, Karl N. , Aksamit, Allen J. , Pittock, Sean J. , Weinshenker, Brian G. , Pittock, S J , Kaufmann, Timothy J. , Keegan, B. Mark , Giannini, Caterina , Flanagan, E P , Weinshenker, Brian G

Annals of Neurology | December 17, 2015 | Volume: 79 | Issue: 3 | Pages: 437-447

10.1002/ana.24582 | PMID 26677112 Get It

ObjectiveTo compare longitudinally extensive myelitis in neuromyelitis optica spectrum disorders (NMOSD) and spinal cord sarcoidosis (SCS).MethodsWe identified adult patients evaluated between 1996 and 2015 with SCS or NMOSD whose first myelitis episode was accompanied by a spinal cord lesion spanning ≥3 vertebral segments. All NMOSD patients were positive for aquaporin‐4–immunoglobulin G, and all sarcoidosis cases were pathologically confirmed. Clinical characteristics were evaluated. Spine magnetic resonance imaging was reviewed by 2 neuroradiologists.ResultsWe studied 71 patients (NMOSD, 37; SCS, 34). Sixteen (47%) SCS cases were initially diagnosed as NMOSD or idiopathic transverse myelitis. Median delay to diagnosis was longer for SCS than NMOSD (5 vs 1.5 months, p < 0.01). NMOSD myelitis patients were more commonly women, had concurrent or prior optic neuritis or intractable vomiting episodes more frequently, had shorter time to maximum deficit, and had systemic autoimmunity more often than SCS (p < 0.05). SCS patients had constitutional symptoms, cerebrospinal fluid (CSF) pleocytosis, and hilar adenopathy more frequently than NMOSD (p < 0.05); CSF hypoglycorrhachia (11%, p = 0.25) and elevated angiotensin‐converting enzyme (18%, p = 0.30) were exclusive to SCS. Dorsal cord subpial gadolinium enhancement extending ≥2 vertebral segments and persistent enhancement >2 months favored SCS, and ringlike enhancement favored NMOSD (p < 0.05). Maximum disability was similar in both disorders.InterpretationSCS is an under‐recognized cause of longitudinally extensive myelitis that commonly mimics NMOSD. We identified clinical, laboratory, systemic, and radiologic features that, taken together, help discriminate SCS from NMOSD. ANN NEUROL 2016;79:437–447
First Do No Harm in End-of-Life Care: A Comment on the 2015 American Heart Association Guidelines for Post-Resuscitation Care of Cardiopulmonary Arrest
Rady, Mohamed Y. , Verheijde, Joseph L.

Journal of Palliative Medicine | December 17, 2015 | Volume: 19 | Issue: 4 | Pages: 349-350

10.1089/jpm.2015.0478 | PMID 26679411 Get It